CONTEXT: Report of a peer reviewed study published in the journal “Therapeutic Advances in Endocrinology and Metabolism” (TAEM) on subcutaneous testosterone pellets for long term hormone therapy in men and women.
IMPACT: low
READ TIME: 2 mins
Quality Level Mean [1 – 10]: 7
1. ““ Clinical experience and research continue to demonstrate the significant negative impact of testosterone deficiency in both women and men on health and well-being, but most delivery methods have been inadequate for long-term therapy: Creams are absorbed inconsistently, injections cause hormone spikes, and previous attempts at patches failed to advance into standard of care because of high rates of side effects,” said study author Dr. Gary Donovitz, who has been a practicing OB/GYN for 30 years and founded hormone optimization company Biote Medical.”
2. “IRVING, Texas–(BUSINESS WIRE)–Delivering testosterone via bioabsorbable pellets inserted under the skin is a low-risk approach to long-term hormone therapy for women and men, according to peer-reviewed data published in the journal “Therapeutic Advances in Endocrinology and Metabolism” (TAEM).”
3. “Each of the 376,254 patients treated for testosterone deficiency received implants of bioidentical hormones, either testosterone alone or combined with estradiol, with 85% of study participants being women, ages 25 to 92, and 15% men, ages 35 to 85.”
4. ““ The safety of hormone pellet implants in men and women over the long term appears to be better than other routes of administration,” said Terry S. Weber, CEO of Biote.”
5. ““ We are hopeful that this study motivates further inquiry so that women and men managing hormone-related conditions like menopause, diabetes and hypogonadism benefit from a broader continuum of care options within standard clinical protocols.””